#	Pagina
attuale pagina	/open-h2020/projects/202967/index.html

Opendata, web and dolomites

EpiHope SIGNED

Epigenetic biomarkers for prediction of vascular complications and response to treatment in subjects with diabetes

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EpiHope project word cloud

Explore the words cloud of the EpiHope project. It provides you a very rough idea of what is the project "EpiHope" about.

thereby progression validated play dna pharmacological quality tool clinical biomarkers follow modifications predict diagnosed pathogenesis opportunity proposing give suggest summary interventions prevention primary efficient clinically methylation glycaemic cvd therapeutics mutations genomic type diseases tissues optimize panel functional therapeutic personalized recruited diabetes forecast appropriate vitro genetic additional outstanding manipulated cardiovascular relevance genome characterization analysed complications pyrosequencing first metformin treatment preventive predictive death epigenetic patients monitor cohort deleterious causes combined risk notably disease time newly pharmacoepigenetics andis vascular scores t2d care epigenetics readily

Project "EpiHope" data sheet

The following table provides information about the project.

Coordinator	LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: Lund postcode: 22100 website: www.lu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	https://www.ludc.lu.se/sonia-garcia-calzon
Total cost	173˙857 €
EC max contribution	173˙857 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2015
Funding Scheme	MSCA-IF-EF-ST
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2018-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LUNDS UNIVERSITET LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: Lund postcode: 22100 website: www.lu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (Lund)	coordinator	173˙857.00

Map

Project objective

Type 2 diabetes (T2D) is one of the leading causes of death through its deleterious effects on cardiovascular disease (CVD). The complications of T2D can be reduced through early and appropriate preventive and therapeutic interventions. Several studies suggest that epigenetics may play a key role in the pathogenesis of these diseases. However, additional studies are needed to improve primary prevention and treatment of T2D and vascular complications. Our overall objective is to identify novel epigenetic biomarkers of clinical relevance that predict, monitor progression and forecast response to treatment of T2D and CVD. First we aim to identify clinically useful epigenetic biomarkers (DNA methylation will be analysed genome-wide) that can predict the glycaemic response to metformin treatment and future risk of CVD in newly diagnosed T2D patients recruited from ANDIS cohort. Second, the most efficient epigenetic biomarkers identified will be validated in T2D patients from ANDIS using pyrosequencing. Third, we aim to make combined predictive risk scores with our novel epigenetic biomarkers, genetic and clinical risk factors to assess risk for CVD. Finally, we will test functional characterization of the validated epigenetic biomarkers in target tissues from T2D patients, and in vitro follow-up studies will be developed. This project represents an outstanding opportunity for personalized treatment for T2D, proposing for the first time pharmacoepigenetics in this field, and also for the development of a panel of high-quality epigenetic biomarkers together with combined risk scores, aiming to give a new reliable clinical tool for early prevention of CVD in T2D patients. Notably, epigenetic modifications can be manipulated more readily than genomic mutations, and thereby has much of potential for pharmacological applications. In summary, the findings of robust epigenetic biomarkers will optimize the therapeutics of T2D and the preventive care of vascular complications.

Publications

List of publications.
year	authors and title	journal	last update
2017	Sonia GarcÃa-CalzÃ³n, Alexander Perfilyev, Ville MÃ¤nnistÃ¶, Vanessa D. de Mello, Emma Nilsson, Jussi PihlajamÃ¤ki, Charlotte Ling Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver published pages: , ISSN: 1868-7075, DOI: 10.1186/s13148-017-0400-0	Clinical Epigenetics 9/1	2019-06-13
2018	Cajsa DavegÃ¥rdh, Sonia GarcÃa-CalzÃ³n, Karl Bacos, Charlotte Ling DNA methylation in the pathogenesis of type 2 diabetes in humans published pages: 12-25, ISSN: 2212-8778, DOI: 10.1016/j.molmet.2018.01.022	Molecular Metabolism 14	2019-06-13
2018	Sonia GarcÃa-CalzÃ³n, Alexander Perfilyev, Vanessa D Mello, Jussi PihlajamÃ¤ki, Charlotte Ling Sex differences in the methylome and transcriptome of the human liver and circulating HDL-cholesterol levels published pages: , ISSN: 0021-972X, DOI: 10.1210/jc.2018-00423	The Journal of Clinical Endocrinology & Metabolism	2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIHOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIHOPE" are provided by the European Opendata Portal: CORDIS opendata.